The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Cognition Biomarkers, 2013Assessment of Plasma Glucosylceramides and Ceramides as Biomarkers of Cognitive Impairment in Parkinson's Disease
Objective/Rationale:
Metabolism of the lipids glucosylceramide and ceramide is altered in Parkinson’s disease (PD). GBA mutations in this pathway, causing a build-up of glucosylceramide, increase the... -
Cognition Biomarkers, 2013[18F]flubatine: A Novel Biomarker of Cognition in Parkinson's Disease
Objective/Rationale:
Mild cognitive impairment and dementia are frequent symptoms of moderate to advanced Parkinson’s disease (PD). Brain positron emission tomography (PET) study findings confirm post... -
Research Grant, 2013Longitudinal Characterization of G2019S Models: Physiological and Behavioral Analyses of Dopamine and Glutamate Systems
Objective/Rationale:
It is likely in disease states that brain cells suffer long periods of dysfunction before they die. By studying the early effects of Parkinson’s disease (PD) gene mutations upon... -
LRRK2 Pharmacodynamic Assays, 2013Monocyte Monitoring in LRRK2-associated Parkinson’s Disease
Objective/Rationale:
LRRK2 variants significantly contribute to the development of familial and sporadic Parkinson’s disease (PD). However, it is not yet understood how LRRK2 mutations cause cellular... -
Research Grant, 2013Evaluation of a LRRK2 Inhibitor in the Partial 6-OHDA-lesioned Model of Parkinson’s Disease
Objective/Rationale:
Mutations in the LRRK2 gene are the most common cause of familial Parkinson’s disease (PD). The existing human genetic, cell-based and model data suggest that LRRK2 kinase... -
Research Grant, 2013Using Whole Genome Sequencing Data from LRRK2 Families to Identify Novel Rare Variants of LRRK2-associated Parkinson’s Disease
Objective/Rationale:
The age of onset and penetrance (likelihood of disease) of individuals with the LRRK2 G2019S mutation varies considerably, the latter ranging in some families from as high as 100...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.